28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia, a progressive neurodegenerative disorder affecting memory, cognition, and behaviour, poses a major global health challenge in aging populations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent studies highlight the significance of plasma phosphorylated tau proteins, neurofilament light chain, and amyloid-beta ratios as reliable biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Parameters such as clinical status, GCA scale, MTA scale, Fazekas scale, strategic infarction, Koedam score, stroke, hypertension, diabetes mellitus, dyslipidemia, and cardiovascular disease do not have significant correlations with MoCA-INA scores. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There was a significant correlation in MoCA and FLCI-2 measures but no significant correlation between the language measures (CIUs, FLCI-2, or word count). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Researchers tested whether a tablet-based cognitive test (TabCAT) could substitute for traditional paper-and-pencil memory tests in people with early-onset Alzheimer's. Scores on the tablet's attention/executive tasks correlated strongly (above 0.7) with standard tests like the MMSE and MoCA, and one subtest could distinguish people with amyloid plaques from those without with good accuracy (AUC 0.82). 5 key findings →
Design: cross-sectional Participants: 475 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Dementia Trials Accelerator (DTA) is a UK-wide programme designed to improve the feasibility, efficiency, and inclusiveness of recruitment into clinical trials of dementia and related brain-health conditions. 5 key findings →
Participants: 10,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using the ADNI dataset, we found that the model realigned patients according to their clinical diagnoses. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early identification of cognitive impairment remains challenging in settings where comprehensive cognitive and clinical assessments are not available. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Middle East and North Africa (MENA) region is projected to experience the fastest growth in dementia burden globally, yet population-based data on cognitive aging remain scarce. 1 key finding →
Participants: 3,027 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONIndividuals with Alzheimers disease (AD) exhibit substantial heterogeneity in the severity of vascular changes and neurodegeneration, making the identification of biologically meaningful subtypes across the AD spectrum critical for improving prognosis and tailoring interventions. 1 key finding →
Design: longitudinal study Participants: 1,396 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings show that model-based, adaptive assessments can support high-frequency, remote detection and scalable longitudinal monitoring of early memory decline, providing a new way to assess memory decline trajectories in healthy aging and dementia. 3 key findings →
Design: longitudinal study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
For TabCAT tests, there were no notable floor or ceiling effects, and test scores were associated with age and education as expected. 3 key findings →
Design: cohort study Participants: 563 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ObjectiveTo investigate whether a lifetime history of DSM-5 AUD and correlated indices of alcohol consumption are associated with accelerated age-related cognitive decline in middle-aged and older adults. 5 key findings →
Design: cross-sectional Participants: 1,421 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MTD showed excellent discrimination of CU versus MCI/DEM (AUC=.89; 95% CI=.87-.92), and discriminability remained high for CU versus MCI (AUC=.88; 95% CI=.85-.92). 5 key findings →
Design: cohort study Participants: 1,224 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sociodemographic and clinical variables routinely recorded in PC EHRs may contribute to dementia identification. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Evidence for interventions that reduce refusal is strongest for music during personal care and modified bathing methods, with some support for positive communication and person-centred approaches, though quality is generally low and few studies involve family caregivers in community settings. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Symptom chronology emerged as a robust diagnostic discriminator, underscoring the clinical value of temporal disease trajectories. 3 key findings →
Participants: 932 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by structural changes of the hippocampus, thus hippocampal morphology becomes an important biomarker for early diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Implementation of an EHR-enabled AD care pathway was associated with improved adoption of guideline-concordant cognitive assessment and recommended diagnostic evaluation in primary care across three health systems. 5 key findings →
Participants: 10,206 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia public stigma was associated with education, dementia knowledge, media exposure, chronic diseases, and contact experience with people living with dementia. 5 key findings →
Design: cross-sectional Participants: 3,055 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with MCI and AD exhibit marked deficits in the performance and accuracy of upper-limb reaching and catching movements when assessed in a VR environment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Medication adherence in older adults was strongly influenced by cognitive impairment, gender, health literacy and cohabitation. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Apathy and depression are among the most common neuropsychiatric symptoms in dementia. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Multimodal integration of cognitive, neuroimaging, and polygenic data in the MHS-RWD tool yields strong discrimination for both early diagnosis of dementia and AD differential diagnosis. 2 key findings →
Participants: 1,100 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →